LBA61 Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
Garassino, M.C., Mazieres, J., Reck, M., Chouaid, C., Bischoff, H., Reinmuth, N., Cove-Smith, L.S., Mansy, T., Cortinovis, D.L., Migliorino, M.R., Delmonte, A., García Sanchez, J., Chara Velarde, L.E., Bernabe Caro, R., Paz-Ares, L., Chander, P., Diaz Perez, I., Foroutanpour, K., Faivre-Finn, C.
Published in Annals of oncology (01.10.2023)
Published in Annals of oncology (01.10.2023)
Get full text
Journal Article